Inventors:
Jay S. Skyler - Key Biscayne FL
Phillip Frost - Miami Beach FL
Elliot F. Hahn - North Miami Beach FL
Assignee:
Baker Norton Pharmaceuticals, Inc. - Miami FL
International Classification:
A61K 3326, A61K 3726
Abstract:
A method of treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus, by administering an effective amount of the compound magnesium vanadate. Daily dosage ranges are preferably from about 2 to about 60 mg per kg of patient body weight. Pharmaceutical compositions for use in the method of treatment include magnesium vanadate and at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.